Why Payers Demand Comparative Evidence for Adjunctive MDD Therapies

Welcome back to another AJMC Insights series. In "Why Payers Demand Comparative Evidence for Adjunctive MDD Therapies," Leslie Citrome, MD, MPH opens this series by unpacking why payers scrutinize branded adjunctive therapies for major depressive disorder so closely.

Dr. Citrome opens by framing the challenge payers face when evaluating the five FDA-approved adjunctive antipsychotics for major depressive disorder. Any disease category that mixes generic and branded options forces a value question. Payers need to know whether a branded product delivers meaningful benefit beyond what a cheaper generic already provides. That question is difficult to answer because no trial has directly compared these five agents against one another. Each was tested individually against placebo during its own registrational program, not against its competitors. Clinicians and payers are therefore forced to rely on indirect comparisons built from separate placebo-controlled trials rather than direct head-to-head evidence. Dr. Citrome explains how this evidentiary gap shapes payer behavior in practice. The prevailing trend, he says, is for payers to reject branded products by default unless a manufacturer proves otherwise. A case must be made that the new intervention offers real advantages over existing options, including the generics already on formulary. To build that case, researchers show how each product compares against placebo individually, then compare those separate placebo comparisons against each other. Dr. Citrome describes this approach as indirect by nature, since it lacks a true head-to-head design. Placebo functions as the common denominator linking otherwise unconnected trials. That indirect appraisal becomes the basis for payer decision-making in the absence of anything stronger. Without it, he cautions, the default assumption is that all agents in a class are functionally interchangeable, undercutting the rationale for approving reimbursement for anything new. This tension between cost, evidence, and formulary access sets up the deeper discussion of network meta-analysis methodology that follows in the next episode.

The next episode in this series, "How Network Meta-Analyses Compare Adjunctive Antipsychotics in MDD," has Dr. Citrome laying the statistical groundwork for everything that follows.